Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 3/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | LTA4H | P09960 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | DRD3 | P35462 | 3/20 | 0.45 |
| ▸ | DRD1 | P21728 | 2/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | EBP | Q15125 | 3/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | ESR1 | P03372 | 2/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3122100 | 0.92 | ALDH1A1 (0.46) | CYP2D6HTTCYP1A2LTA4HCYP2C9 | |
| SCHEMBL161444 | 0.82 | HTR7 (0.47) | CYP2D6HTTCYP1A2LTA4HKDM4E | |
| SCHEMBL5251458 | 0.80 | HTR1A (0.36) | CYP2D6HTTCYP1A2LTA4HCYP2C9 | |
| SCHEMBL126227 | 0.80 | ALDH1A1 (0.34) | HTTCYP1A2LTA4HCYP2C9CYP2C19 | |
| SCHEMBL6238419 | 0.79 | JAK2 (0.33) | HTTKDM4EALDH1A1LMNAMAPT | |
| SCHEMBL219417 | 0.79 | KDM4E (0.56) | KDM4EALDH1A1DRD3SIGMAR1KMT2A | |
| SCHEMBL49991 | 0.78 | LTA4H (0.46) | CYP2D6CYP1A2LTA4HCYP2C9CYP2C19 | |
| SCHEMBL6633045 | 0.78 | LTA4H (0.49) | LTA4HKCNH2ESR1CHRM2CHRM1 | |
| SCHEMBL3125003 | 0.77 | LSS (0.49) | KDM4EALDH1A1HRH3 | |
| SCHEMBL167283 | 0.77 | LTA4H (0.46) | HTTCYP1A2LTA4HCYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7868018-B2 | such as N [3-(2-(3-trifluoromethyl)-benzoylamino -[1,6]naphthyridin-3-yl)-2,4-dichloro-phenyl]-3-trifluoromethyl-benzamide, used as antiproliferative agents or for the treatment of autoimmune diseases and nervous system disorders | IRM LLC (BM) | 2011-01-11 | — | — | US | claimed |
| WO-2010036316-A1 | UREA AND CARBAMATE COMPOUNDS AND ANALOGS AS KINASE INHIBITORS | FENG YANGBO (US) | 2010-04-01 | — | — | WO | claimed |
| EP-2099797-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM, LLC (BM) | 2009-09-16 | — | — | EP | claimed |
| US-20080300246-A1 | Compounds and Compositions as Protein Kinase Inhibitors | IRM LLC (BM) | 2008-12-04 | — | — | US | claimed |
| WO-2007021795-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2007-02-22 | — | — | WO | claimed |
| US-5665780-A | DEACTIVATING P-GLYCOPROTEIN PUMP IN TUMORS; CANCER TREATMENT | MERRELL PHARMACEUTICALS INC. (US) | 1997-09-09 | — | — | US | claimed |
| EP-0624090-B1 | REVERSAL OF MULTI-DRUG RESISTANCE BY TETRAARYLETHYLENES | MERRELL PHARMA INC (US) | 1996-09-18 | — | — | EP | claimed |
| EP-0624090-A1 | REVERSAL OF MULTI-DRUG RESISTANCE BY TETRAARYLETHYLENES. | MERRELL DOW PHARMA (US) | 1994-11-17 | — | — | EP | claimed |
| WO-1993015733-A1 | REVERSAL OF MULTI-DRUG RESISTANCE BY TETRAARYLETHYLENES | MERRELL DOW PHARMACEUTICALS INC. (US) | 1993-08-19 | — | — | WO | claimed |
| EP-0093515-B1 | TRICYCLIC TRIAZINO COMPOUNDS, THEIR USE AND FORMULATION AS PHARMACEUTICALS AND PROCESSES FOR THEIR PRODUCTION | FISONS plc (GB) | 1987-01-21 | — | — | EP | claimed |
| US-4499269-A | IMMUNO-REGULANT, SKIN DISORDERS, ANTITUMOR AGENTS | FISONS PLC (GB) | 1985-02-12 | — | — | US | claimed |
| EP-0093515-A1 | Tricyclic triazino compounds, their use and formulation as pharmaceuticals and processes for their production | FISONS plc (GB) | 1983-11-09 | — | — | EP | claimed |
| CN-102532162-B | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMA CO LTD | 2015-05-27 | — | — | CN | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-7868018-B2 | such as N [3-(2-(3-trifluoromethyl)-benzoylamino -[1,6]naphthyridin-3-yl)-2,4-dichloro-phenyl]-3-trifluoromethyl-benzamide, used as antiproliferative agents or for the treatment of autoimmune diseases and nervous system disorders | IRM LLC (BM) | 2011-01-11 | — | — | US | disclosed |
| WO-1993015733-A1 | REVERSAL OF MULTI-DRUG RESISTANCE BY TETRAARYLETHYLENES | MERRELL DOW PHARMACEUTICALS INC. (US) | 1993-08-19 | — | — | WO | disclosed |
| EP-0093515-B1 | TRICYCLIC TRIAZINO COMPOUNDS, THEIR USE AND FORMULATION AS PHARMACEUTICALS AND PROCESSES FOR THEIR PRODUCTION | FISONS plc (GB) | 1987-01-21 | — | — | EP | disclosed |
| US-4499269-A | IMMUNO-REGULANT, SKIN DISORDERS, ANTITUMOR AGENTS | FISONS PLC (GB) | 1985-02-12 | — | — | US | disclosed |
| EP-0093515-A1 | Tricyclic triazino compounds, their use and formulation as pharmaceuticals and processes for their production | FISONS plc (GB) | 1983-11-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300246-A1 | Compounds and Compositions as Protein Kinase Inhibitors | SGK2, BRSK2, FYN | CYP2D6 4412/4885HTT 3062/4885CYP1A2 4438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.